



Substitute for form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Attorney Docket No: AC-21-US

Complete If Known

Application Number	10/522,208
Filing Date	October 27, 2005
First Named Inventor	Ali et al.
Art Unit	1625
Examiner Name	Chang, Celia C.

US PATENT DOCUMENTS

Examiner Initials*	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date if Appropriate
/CC/		4,639,436	01-1987	Junge et al.	
		5,798,366	8-1998	Platt et al.	
		6,426,198	7-2002	Carstea et al.	
		6,495,570	12-2002	Jacob et al.	
		6,683,076	01-2004	Walkley et al.	
		20010044453	11-2001	Jacob et al.	
		20060058349	03-2006	Hussein et al.	
		20060074107	04-2006	Butters et al.	
		20060111400	05-2006	Hussein et al.	
		20070112028	05-2007	Orchard et al.	
		20070259918	11-2007	Orchard	
/CC/		20080234324	09-2008	Scopes et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²
/CC/		WO 92/00277	09 Jan 1992	Nippon Shinyaku Co., Ltd.	
		WO 94/26714	24 Nov 1994	G.D. Searle & Co.	
		WO 98/02161	22 Jan 1998	Universiteit Van Amsterdam	
		WO 98/30219	16 Jul 1998	Monsanto Company	
		WO 99/24401	20 May 1999	G.D. Searle & Co.	
/CC/		WO 00/33843	15 Jun 2000	G.D. Searle & Co., et al.	

EXAMINER

/Celia Chang/

DATE CONSIDERED 6/1/2009

Substitute for form 1449A/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/522,208
				Filing Date	October 27, 2005
				First Named Inventor	Ali et al.
				Art Unit	1625
				Examiner Name	Chang, Celia C.
				(Use as many sheets as necessary)	
Sheet	2	of	3	Attorney Docket No: AC-21-US	

/CC/	WO 00/56334	28 Sep 2000	The Trustees of Boston College	
	WO 00/62780	26 Oct 2000	Oxford Glycosciences (UK) Ltd.	
	WO 01/10429	15 Feb 2001	Zitzmann et al.	
	WO 04/007453	22 Jan 2004	Oxford Glycosciences (UK) Ltd.	
	WO 04/007454	22 Jan 2004	Oxford Glycosciences (UK) Ltd.	
	WO 04/111001	23 Dec 2004	Oxford Glycosciences (UK) Ltd.	
	WO 04/111002	23 Dec 2004	Oxford Glycosciences (UK) Ltd.	
	WO 05/068426	28 Jul 2005	Cell-Tech R&D Limited	
	EP 0491041	24 Jun 1992	Nippon Shinyaku Co. Ltd.	
/CC/	JP 3-24057	01 Feb 1991	Tosoh Corp.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/CC/		ABE et al., Induction of glucosylceramide synthase by synthase inhibitors and ceramide, BBA, 1299, 333-341 (1996)		
		BUTTERS et al., Therapeutic applications of imino sugars in lysosomal storage disorders, Current Topics in Medicinal Chemistry, 3, 561-574 (2003)		
		CAREY, Organic Chemistry, 2 nd Edition, Pages 28-29, 268-271		
		MELLOR, High-performance cation-exchange chromatography and pulsed amperometric detection for the separation, detection, and quantitation of N-alkylated imino sugars in biological samples, Analytical Biochemistry, XP-001055984, 284, 136-142 (2000)		
		MERZAK et al., Gangliosides modulate proliferation, migration, and invasiveness of human brain tumor cells <i>in vitro</i> , Mol. & Chem. Neuropathology, 24, 121-135 (1995)		
		MORRISON et al., Organic Chemistry, 5 th Edition, Pages 138-141		
		OVERKLEET et al., Generation of specific deoxyxojirimycin-type inhibitors of the non-lysosomal glucosylceramidase, J. of Biol. Chem. 273(41), 26522-26527 (1998)		
		PLATT et al., N-Butyldeoxyojirimycin is a novel inhibitor of glycolipid biosynthesis, 269(11), 8362-8365 (1994)		
/CC/		SCHALLER et al., Total synthesis of (+)- and (-)-1-deoxyojirimycin (1,5-dideoxy-1,5-imino-D-and L-glucitol) and of (+)- and (-)-1-deoxyidojirimycin(1,5-dideoxy-1,5-imino-D and L-iditol) via furoisoxazoline-3-aldehydes, Carbohydrate Res., 314, 25-35, (1998)		

EXAMINER	/Celia Chang/	DATE CONSIDERED	6/1/2009
----------	---------------	-----------------	----------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	3	of	3
Attorney Docket No: AC-21-US			
<i>Complete if Known</i>			
Application Number		10/522,208	
Filing Date		October 27, 2005	
First Named Inventor		Ali et al.	
Art Unit		1625	
Examiner Name		Chang, Celia C.	

/CC/	SCHNEIDER, GM1 ganglioside in the treatment of Parkinson's Disease, Ann. NY Acad. Sci., 845, 363-373 (1998)	
/CC/	TYLE, Iontophoretic devices for drug delivery, Pharm. Res., 3, 318-326 (1986)	
/CC/	VAN DER SPOEL, et al., Proc. Natl. Acac. Sci. USA, 99(26), 17173-17178 (2002)	

EXAMINER /Celia Chang/

DATE CONSIDERED 6/1/2009

Substitute Disclosure Statement Form (PTO-1449)

- EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 2 Applicant's unique citation designation number (optional) 3 Applicant is to place a check mark here if English language translation is attached